Antonella Zucchetto

Anti-CD138 Antibody-Conjugated Chitosan Nanobubbles for Targeting of Multiple Myeloma and Reverting Tumor Microenvironmental Invasiveness

Carmela Tangredi, Monica Argenziano, Davide Busato, Sara Capolla et autres

it (code pays fourni par la source)

CD49d expression is epigenetically regulated in chronic lymphocytic leukemia: Insights from CD49d bimodal cases

Erika Tissino, Nicola Calonaci, Federico Pozzo, Lodovico Terzi di Bergamo et autres

Abstract CD49d (integrin α4) is a key adhesion molecule in chronic lymphocytic leukemia (CLL) with prognostic relevance. While most cases show uniform CD49d expression, ~20% display a bimodal pattern with CD49d+ and CD49d– subpopulations originating from the same leukemic clone. In bimodal …

it, ch (code pays fourni par la source)

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Luca Laurenti, Antonio Mosca, Candida Vitale, Maria Chiara Montalbano et autres

Abstract Introduction: Covalent Bruton tyrosine kinase inhibitors (cBTKi) have revolutionized the treatment of Chronic Lymphocytic Leukemia (CLL). They target Bruton tyrosine kinase (BTK), which mediates BCR signaling, and triggers pathways involved in cell survival, proliferation and migration. BTK inhibition in neoplastic lymphocytes …

it, ua (code pays fourni par la source)

CLL-1206: Prevalence and Clinical Impact of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia

Samir Mouhssine, Chiara Cosentino, Mohammad Almasri, Ilaria Jane Romano et autres

Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens

Claudia Matteucci, Vita Petrone, Alessandro Giovinazzo, Roberta Laureana et autres

ABSTRACT: Dysregulated expression of human endogenous retrovirus K (HERV-K) has been found in many types of tumors. Previously, we demonstrated the concomitant expression of HERVs and embryonic genes in cancer cells with aggressive and stemness features. In the field of onco-hematology, some …

it, us (code pays fourni par la source)

Figure S17 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei et autres

Sensitivity to ibrutinib was evaluated by MTT assay (72h). Karpas1718 parental (top) or resistant (bottom) were exposed to 100nM decitabine (A), 5µM tazemetostat (B), or DMSO (control, black) given concomitantly (continuous lines) or 72 hours before ibrutinib (pre DMSO in dashed black …

Figure S1 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei et autres

Multi-drug resistance phenotype was ruled out by the expression of MDR1 (left) and MDR2 (right) genes by real time PCR. RQ values calculated by the DDCt method. Karpas1718 (K1718) parental lines in grey and resistant in red. Data derived from two independent …

Figure S12 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei et autres

(A) Cell viability for the combination of idelalisib and the ERBB inhibitor lapatinib in parental and resistant by MTT assay (72h). Bars correspond to the mean of two independent experiments. Error bars represent standard deviation of the mean. Table contains p-values from …

Figure S5 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei et autres

Parental (green) and resistant (orange) levels of DNA promoter methylation (A) and gene expression (RNA-seq, B) of DUSP4, and p-ERK upon 1µM of idelalisib (Flow cytometry).

Figure S19 and references for supplementary figures from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei et autres

Factors associated with resistance to idelalisib in cell lines are expressed in clinical specimens. Expression levels of genes related to idelalisib resistance were studied across different subtypes of B cell lymphoma: (A) n=48 (5), (B) n=80 (6). B-CLL: chronic lymphocytic leukemia, B.FL: …

Figure S14 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei et autres

Karpas1718 parental (A-B), SP53 (C-D), OCILY10 (C, E) and JEKO1-Cas9-ERBB4 (F-G) cells were exposed with DMSO (grey), idelalisib (red) or idelalisib + lapatinib (yellow) for 2-weeks. Expression levels of let-7c and miR-29c miRNAs (real-time PCR); and surface ERBB4 and intracellular HBEGF (both …

Figure S15 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei et autres

Resistant in parallel with parental clones of Karpas1718 cell line were exposed to a library of 348 compounds alone (single, 1µM) or in combination with 1µM idelalisib (combo) for 72h. Cell viability was measured by MTT assay (72h). Yellow for benefit in …